Cisplatin and novobiocin in the treatment of non-small cell lung cancer: A Southwest Oncology Group study

G. K. Ellis, Robert B Livingston, R. B. Livingston, J. W. Goodwin, L. Hutchins, A. Allen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Novobiocin, a commercially available oral antibiotic, inhibits DNA topoisomerase II in a manner shown in cell culture to enhance the cytotoxicity of alkylating agents and cisplatin. Thirty-six patients were entered on a Phase II trial using high-dose cisplatin (100 mg/m2 on days 1 and 8 for four cycles) after steady-state dosing with novobiocin (1000 mg or four 250-mg capsules every 12 hours for six doses, four of which were administered before each dose of cisplatin). One patient remains on study and cannot be evaluated for response. No complete responses were seen. Three patients (8%) had partial responses and an additional patient had an unconfirmed partial response. The median survival time of all patients was just less than 7 months. These results are comparable with those of other concurrent Southwest Oncology Group (SWOG) Phase II and III trials of high-dose cisplatin in non-small cell lung cancer (NSCLC). Novobiocin plasma levels were obtained for three patients and were approximately 50% of the optimal concentration as reported in cell culture for potentiation of cytotoxicity. It was concluded that an optimum test of novobiocin as a modulator of cytotoxicity may require the availability of an intravenous preparation.

Original languageEnglish (US)
Pages (from-to)2969-2973
Number of pages5
JournalCancer
Volume67
Issue number12
StatePublished - 1991
Externally publishedYes

Fingerprint

Novobiocin
Non-Small Cell Lung Carcinoma
Cisplatin
Therapeutics
Cell Culture Techniques
Type II DNA Topoisomerase
Alkylating Agents
Capsules
Anti-Bacterial Agents
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ellis, G. K., Livingston, R. B., Livingston, R. B., Goodwin, J. W., Hutchins, L., & Allen, A. (1991). Cisplatin and novobiocin in the treatment of non-small cell lung cancer: A Southwest Oncology Group study. Cancer, 67(12), 2969-2973.

Cisplatin and novobiocin in the treatment of non-small cell lung cancer : A Southwest Oncology Group study. / Ellis, G. K.; Livingston, Robert B; Livingston, R. B.; Goodwin, J. W.; Hutchins, L.; Allen, A.

In: Cancer, Vol. 67, No. 12, 1991, p. 2969-2973.

Research output: Contribution to journalArticle

Ellis, GK, Livingston, RB, Livingston, RB, Goodwin, JW, Hutchins, L & Allen, A 1991, 'Cisplatin and novobiocin in the treatment of non-small cell lung cancer: A Southwest Oncology Group study', Cancer, vol. 67, no. 12, pp. 2969-2973.
Ellis GK, Livingston RB, Livingston RB, Goodwin JW, Hutchins L, Allen A. Cisplatin and novobiocin in the treatment of non-small cell lung cancer: A Southwest Oncology Group study. Cancer. 1991;67(12):2969-2973.
Ellis, G. K. ; Livingston, Robert B ; Livingston, R. B. ; Goodwin, J. W. ; Hutchins, L. ; Allen, A. / Cisplatin and novobiocin in the treatment of non-small cell lung cancer : A Southwest Oncology Group study. In: Cancer. 1991 ; Vol. 67, No. 12. pp. 2969-2973.
@article{1b375f7e4f774cbf98f3dc5f80cca492,
title = "Cisplatin and novobiocin in the treatment of non-small cell lung cancer: A Southwest Oncology Group study",
abstract = "Novobiocin, a commercially available oral antibiotic, inhibits DNA topoisomerase II in a manner shown in cell culture to enhance the cytotoxicity of alkylating agents and cisplatin. Thirty-six patients were entered on a Phase II trial using high-dose cisplatin (100 mg/m2 on days 1 and 8 for four cycles) after steady-state dosing with novobiocin (1000 mg or four 250-mg capsules every 12 hours for six doses, four of which were administered before each dose of cisplatin). One patient remains on study and cannot be evaluated for response. No complete responses were seen. Three patients (8{\%}) had partial responses and an additional patient had an unconfirmed partial response. The median survival time of all patients was just less than 7 months. These results are comparable with those of other concurrent Southwest Oncology Group (SWOG) Phase II and III trials of high-dose cisplatin in non-small cell lung cancer (NSCLC). Novobiocin plasma levels were obtained for three patients and were approximately 50{\%} of the optimal concentration as reported in cell culture for potentiation of cytotoxicity. It was concluded that an optimum test of novobiocin as a modulator of cytotoxicity may require the availability of an intravenous preparation.",
author = "Ellis, {G. K.} and Livingston, {Robert B} and Livingston, {R. B.} and Goodwin, {J. W.} and L. Hutchins and A. Allen",
year = "1991",
language = "English (US)",
volume = "67",
pages = "2969--2973",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Cisplatin and novobiocin in the treatment of non-small cell lung cancer

T2 - A Southwest Oncology Group study

AU - Ellis, G. K.

AU - Livingston, Robert B

AU - Livingston, R. B.

AU - Goodwin, J. W.

AU - Hutchins, L.

AU - Allen, A.

PY - 1991

Y1 - 1991

N2 - Novobiocin, a commercially available oral antibiotic, inhibits DNA topoisomerase II in a manner shown in cell culture to enhance the cytotoxicity of alkylating agents and cisplatin. Thirty-six patients were entered on a Phase II trial using high-dose cisplatin (100 mg/m2 on days 1 and 8 for four cycles) after steady-state dosing with novobiocin (1000 mg or four 250-mg capsules every 12 hours for six doses, four of which were administered before each dose of cisplatin). One patient remains on study and cannot be evaluated for response. No complete responses were seen. Three patients (8%) had partial responses and an additional patient had an unconfirmed partial response. The median survival time of all patients was just less than 7 months. These results are comparable with those of other concurrent Southwest Oncology Group (SWOG) Phase II and III trials of high-dose cisplatin in non-small cell lung cancer (NSCLC). Novobiocin plasma levels were obtained for three patients and were approximately 50% of the optimal concentration as reported in cell culture for potentiation of cytotoxicity. It was concluded that an optimum test of novobiocin as a modulator of cytotoxicity may require the availability of an intravenous preparation.

AB - Novobiocin, a commercially available oral antibiotic, inhibits DNA topoisomerase II in a manner shown in cell culture to enhance the cytotoxicity of alkylating agents and cisplatin. Thirty-six patients were entered on a Phase II trial using high-dose cisplatin (100 mg/m2 on days 1 and 8 for four cycles) after steady-state dosing with novobiocin (1000 mg or four 250-mg capsules every 12 hours for six doses, four of which were administered before each dose of cisplatin). One patient remains on study and cannot be evaluated for response. No complete responses were seen. Three patients (8%) had partial responses and an additional patient had an unconfirmed partial response. The median survival time of all patients was just less than 7 months. These results are comparable with those of other concurrent Southwest Oncology Group (SWOG) Phase II and III trials of high-dose cisplatin in non-small cell lung cancer (NSCLC). Novobiocin plasma levels were obtained for three patients and were approximately 50% of the optimal concentration as reported in cell culture for potentiation of cytotoxicity. It was concluded that an optimum test of novobiocin as a modulator of cytotoxicity may require the availability of an intravenous preparation.

UR - http://www.scopus.com/inward/record.url?scp=0025819479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025819479&partnerID=8YFLogxK

M3 - Article

C2 - 1646065

AN - SCOPUS:0025819479

VL - 67

SP - 2969

EP - 2973

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -